# Oxulumis®, Suprachoroidal Drug Administration of Triesence® in Diabetic Macular Edema

> **NCT05172401** · NA · WITHDRAWN · sponsor: **Oxular Limited**

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DEVICE:** Oxulumis® suprachoroidal microcatheterization administration of Triesence®

## Key facts

- **NCT ID:** NCT05172401
- **Lead sponsor:** Oxular Limited
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-09-15
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** unforeseen, continued (\>12month) global shortage of study medication. Study Drug Triesence, manufacturer Novartis, not supplied throughout 2022
- **Last updated:** 2023-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05172401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05172401, "Oxulumis®, Suprachoroidal Drug Administration of Triesence® in Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05172401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*